Atherotech is a privately held cardio-diagnostic company focusing on direct measurement of the comprehensive lipid profile using the company's VAP (Vertical Auto Profile) technology. The VAP technology is a patented density gradient ultracentrifugation that directly measures the cholesterol content of all lipids, components, and subclasses. The company provides its unique testing services to physicians, hospitals, clinics, and other laboratories throughout the United States. Atherotech is a CLIA approved clinical reference laboratory located in Birmingham, Alabama.
About The VAP Test
The VAP Test was developed by Jere Segrest, M.D., internal medicine physician, acting professor, and director of the Atherosclerosis Research Unit at the University of Alabama, Birmingham. The test is an expanded cholesterol profile that provides direct, detailed measurements of cholesterol, or lipid, subclasses, which play important roles in the development of cardiovascular disease, the No. 1 cause of death in the United States. The test identifies a far greater number of people at risk for heart disease than traditional cholesterol tests developed in the 1970s. Measurements obtained using The VAP Test also provide doctors with a foundation from which to develop individualized treatment plans while continuing to track patients' progress in battling heart disease. The price of the VAP Test is comparable to the traditional cholesterol test, and is reimbursed by Medicare and most insurance carriers. Atherotech has its accuracy confirmed by the CORE Laboratory at Washington University in St. Louis, MO.
Behrman Capital is the majority shareholder of Atherotech.